Proteon Therapeutics (PRTO) Reports Q2 Loss of $0.31/Share

Proteon Therapeutics (NASDAQ: PRTO) reported Q2 EPS of ($0.31), versus ($18.55) reported last year.

Cash, cash equivalents and available-for-sale investments totaled $74.7 million as of June 30, 2015, compared to $83.6 million as of December 31, 2014. The decrease was driven by operational costs for the first six-month period of 2015.

For earnings history and earnings-related data on Proteon Therapeutics (PRTO) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c